Abbott Laboratories Hovers Just Above 52-Week Low as Shares Stall at $83.84

By TrendSpider Editor

The broader setup for Abbott remains challenging from a purely price-based perspective. The stock has been in a prolonged downtrend when measured against its 52-week high, and today's 0.02% move offers little evidence that a trend reversal is underway. Yesterday's session saw ABT trade between $82.6

Abbott Laboratories Hovers Just Above 52-Week Low as Shares Stall at $83.84

Abbott Laboratories is trading at $83.84 on Thursday, May 14, 2026, up just 0.02% on the session, a move that is more flatline than recovery. With a 52-week range spanning from $81.97 to $139.05, ABT sits uncomfortably close to its annual floor, trading only $1.87 above its 52-week low and roughly 40% below its 52-week high.

Key Drivers of the ABT Stock Move

The broader setup for Abbott remains challenging from a purely price-based perspective. The stock has been in a prolonged downtrend when measured against its 52-week high, and today's 0.02% move offers little evidence that a trend reversal is underway. Yesterday's session saw ABT trade between $82.69 and $84.2625, a range that captures the current indecision in the stock. With shares pinned near multi-year lows, investors will be watching closely to see whether the $81.97 support level holds or gives way, which could open the door to further downside. Until ABT can demonstrate a meaningful recovery off this base and reclaim higher ground with conviction, the technical picture remains under pressure.

ABT Seasonality

Mid-May has historically represented a transitional period for large-cap healthcare names as investors digest Q1 earnings results and reposition ahead of summer. For a stock already trading near a 52-week low in mid-May, seasonal patterns suggest the next few weeks could be a critical window for either stabilization or a further breakdown.

ABT Relative Performance

At $83.84, ABT is trading just 2.3% above its 52-week low of $81.97, which stands in stark contrast to broader market performance over the same period. The stock's position at the extreme low end of its annual range suggests significant underperformance relative to both the broader healthcare sector and large-cap indices, which have generally held up better than a nearly 40% drawdown from 52-week highs would imply for a company of Abbott's size and profile.